MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.
This clinical trial summary provides the background and rationale for a randomized trial, MAGRIT, to investigate the efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) agents in preventing cancer relapse, when administered after tumor resection, in patients with MAGE-A3-positive stages IB, II, and IIIA non-small-cell lung cancer. The study will also evaluate potential side effects of MAGE-A3 ASCIs. The primary endpoint is disease-free survival. The secondary endpoint is prospective validation of the gene signature predictive of benefit from MAGE-A3 ASCI therapy.
Tyagi
Preeta
P
GlaxoSmithKline Oncology, Collegeville, PA 19426, USA. preeta.3.tyagi@gsk.com
Mirakhur
Beloo
B
D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D015415:Biomarkers; D019496:Cancer Vaccines; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D020869:Gene Expression Profiling; D006801:Humans; D016233:Immunotherapy, Active / Q000009:adverse effects; D008175:Lung Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D055502:Secondary Prevention; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D015415:Biomarkers; D019496:Cancer Vaccines; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins; D011994:Recombinant Proteins